Can You Take Letrozole and Progesterone Together?

Letrozole and progesterone are frequently prescribed together, particularly in fertility treatment, and there is no blanket pharmacological reason they cannot be combined. The two drugs act on different hormonal pathways, so one does not directly block or amplify the other in a dangerous way. That said, whether combining them actually helps depends heavily on why you’re taking each one. In fertility protocols, for endometriosis, and in breast cancer care, the evidence points in surprisingly different directions.

What Each Drug Does and Why They Get Paired

Letrozole belongs to a class of drugs called aromatase inhibitors. It works by blocking the enzyme aromatase, which your body uses to produce estrogen. Modern aromatase inhibitors like letrozole are highly selective, meaning they shut down estrogen production without interfering with other hormone-making pathways.¹ In fertility medicine, this estrogen suppression tricks the brain into ramping up signals that stimulate the ovaries, leading to ovulation. In breast cancer treatment, the goal is simply to starve estrogen-dependent tumors of their fuel.

Progesterone is a hormone your body naturally produces after ovulation. It prepares and maintains the uterine lining for a potential pregnancy. When prescribed as a medication, it’s typically given as vaginal suppositories, oral capsules, or injections. In fertility treatment, supplemental progesterone during the “luteal phase” (the roughly two weeks between ovulation and either a period or a positive pregnancy test) is meant to shore up the uterine lining and support early implantation.

The pairing makes intuitive sense: letrozole helps you ovulate, and progesterone helps the resulting pregnancy stick. But intuition and evidence don’t always align.

Luteal Progesterone Support After Letrozole for Ovulation Induction

If you’re taking letrozole to induce ovulation and your doctor has also prescribed vaginal progesterone for luteal support, the research on whether the progesterone actually improves your chances is mixed. A study looking at ovarian stimulation cycles with letrozole found no meaningful difference in clinical pregnancy rates between women who received vaginal progesterone and those who did not. The pregnancy rate was about 12% in the progesterone group and about 13% without it, and after adjusting for factors like age and body mass index, the odds of pregnancy were statistically unchanged.²

This doesn’t mean progesterone is useless in all letrozole cycles. It means that for the general population of women using letrozole for ovulation induction, adding progesterone may not move the needle. The thinking is that because letrozole-stimulated cycles tend to produce a more natural hormonal pattern than, say, injectable gonadotropin cycles, the body’s own progesterone production after ovulation may already be sufficient. Your doctor might still prescribe it as a precaution, since vaginal progesterone carries minimal risk, but the evidence for a clear benefit in this broad group is thin.

When PCOS Changes the Equation

The picture shifts when polycystic ovary syndrome is in play. Women with PCOS often have disrupted hormonal patterns even after successful ovulation, which can include insufficient progesterone production in the luteal phase. In a study of women with PCOS using letrozole for ovulation induction, those who received intravaginal progesterone support had clinical pregnancies in about 21% of cycles, compared with zero pregnancies in cycles without progesterone support.³

That’s a striking difference, though the study was small enough that the zero-pregnancy comparison group included only 13 cycles. Still, the researchers concluded that luteal progesterone supplementation should be strongly considered in women with PCOS who are using letrozole. This aligns with the broader understanding that PCOS can impair the corpus luteum (the structure left behind after ovulation that produces progesterone), making external support more valuable. If you have PCOS and are taking letrozole to conceive, progesterone supplementation is one of the more evidence-supported add-ons your fertility specialist can offer.

Safety for Pregnancy and the Baby

A common concern when combining fertility medications is whether they pose risks to a developing pregnancy. For letrozole specifically, a large study found no increased risk of major birth defects compared with natural-cycle conceptions. The rate of major congenital anomalies was about 1.5% in natural cycles and about 1.9% in letrozole cycles, a difference that was not statistically meaningful. The same study also found that the risk of miscarriage was actually lower in the letrozole group.⁴

Progesterone supplementation in early pregnancy is itself well-studied and generally considered safe, as it mimics what the body produces naturally. The combination of having used letrozole for ovulation induction and then taking progesterone for luteal support does not appear to create any compounding safety concern for the pregnancy.

The Breast Cancer Context Is Entirely Different

If you’re taking letrozole as part of breast cancer treatment rather than for fertility, the question of adding progesterone carries a different set of stakes. Letrozole is prescribed to postmenopausal women (or premenopausal women on ovarian suppression) with estrogen receptor-positive breast cancer, often for five or more years. Its job in this setting is to keep estrogen levels as low as possible to prevent cancer recurrence.

Progesterone’s role in breast cancer biology is more complicated than estrogen’s, but the clinical guidance is clear: women who currently have estrogen receptor-positive breast cancer, or who have had it in the past, are generally advised not to take sex hormones, including progesterone.⁵ This recommendation exists because progesterone has been associated with tumor cell proliferation in some studies, and the interplay between estrogen receptors and progesterone receptors in breast tissue is still being worked out.

Research on fertility preservation for breast cancer patients illustrates this tension. When letrozole is used alongside ovarian stimulation to help cancer patients freeze eggs before chemotherapy, it successfully keeps estrogen levels low. However, progesterone levels during these cycles remain high, comparable to what you’d see in standard IVF stimulation without letrozole.⁶ The researchers flagged this as a concern, recommending that modified protocols be investigated to reduce progesterone exposure in these patients.

Emerging Research on Letrozole Plus Progesterone in Breast Cancer

Despite the cautious stance, some researchers are actively testing whether micronized progesterone might actually be safe, or even helpful, alongside letrozole in early breast cancer. A window-of-opportunity trial (the WinPro trial) looked at what happened when micronized progesterone was added to letrozole during the brief period between diagnosis and surgery. The study measured Ki67, a marker of how actively cancer cells are dividing. Letrozole alone suppressed Ki67 by about 88%, while letrozole plus micronized progesterone suppressed it by about 89%, with no meaningful difference between the two groups.⁷

One practical finding from the same trial: hot flushes, one of the most complained-about side effects of letrozole, appeared less frequent in the group receiving letrozole plus progesterone (about 13%) compared with letrozole alone (about 22%). That’s a potentially meaningful quality-of-life difference for women who take letrozole for years. But a window-of-opportunity study is a short-term snapshot, not a long-term safety trial. Whether adding progesterone to letrozole for years would be safe for cancer outcomes remains an open question that larger trials will need to answer.

Separately, some clinical research has explored whether progestins (synthetic progesterone-like drugs) might have a place in treating advanced breast cancer. Trials of progestins like megestrol acetate have shown clinical benefit even in women whose cancer had stopped responding to aromatase inhibitors or tamoxifen.⁸ This line of research is still evolving, and the mechanisms by which progesterone receptor signaling affects breast cancer are far from settled. For now, the standard recommendation remains not to supplement with progesterone while on letrozole for breast cancer, outside of a clinical trial.

Letrozole and Progestins for Endometriosis

Endometriosis is another condition where letrozole and a form of progesterone end up prescribed together, and here the combination is more established. Endometriotic tissue produces its own estrogen via local aromatase activity, which is part of why the disease can be so persistent. Letrozole cuts off that local estrogen supply, while a progestin (a synthetic progesterone) counteracts the endometrial thinning that letrozole alone would cause and adds its own anti-inflammatory effects.

A pilot study combining letrozole with norethindrone acetate (a progestin) for six months in women with endometriosis and chronic pelvic pain found significant improvements. Pain scores dropped from an average of about 6.2 out of 10 before treatment to about 2.5 during treatment, a reduction that held even a month after stopping therapy. Disease staging also improved in all ten patients.⁹

A randomized trial compared letrozole plus norethisterone acetate against letrozole plus triptorelin (a different type of hormonal drug) for endometriosis-related pain. Both combinations reduced pelvic pain and deep pain during intercourse to a similar degree. But the progestin combination was much better tolerated: only about 6% of women in the progestin group had to stop treatment due to side effects, compared with about 44% in the triptorelin group. The progestin group also preserved bone mineral density, which decreased in the triptorelin group.¹⁰

More recent research has explored combining letrozole with dydrogesterone (another progestin) and found that the combination reduced the size of endometriotic lesions, suppressed cell proliferation, and decreased inflammation, with trends suggesting it outperformed either agent alone or standard treatments like dienogest and leuprolide.¹¹ Endometriosis management is one area where the letrozole-progestin combination has a genuinely strong rationale and a growing evidence base.

Side Effects When the Two Are Combined

Neither letrozole nor progesterone has a particularly harsh side-effect profile in the short-term dosing used for fertility treatment. Letrozole’s most common side effects during ovarian stimulation include mild headache, fatigue, and occasionally hot flushes. A randomized trial comparing letrozole co-treatment with placebo during IVF stimulation found no serious adverse events in either group. There was actually a trend toward less nausea and vomiting in the letrozole group, with about 28% reporting those symptoms compared to 44% in the placebo group, though this difference didn’t reach statistical significance.¹²

Vaginal progesterone can cause local irritation, discharge, and sometimes drowsiness or bloating. Oral micronized progesterone tends to cause more drowsiness than vaginal forms, which is why it’s often prescribed at bedtime. When the two drugs are combined in fertility protocols, there’s no known synergistic side effect that emerges from the pairing. You simply get the side-effect profile of each drug individually.

For longer-term use in endometriosis treatment, the combination of letrozole with a progestin also appears reasonably well tolerated. The progestin component helps counteract one of the key concerns with long-term aromatase inhibitor use: bone density loss. Letrozole on its own, by suppressing estrogen, can accelerate bone thinning over months or years. The progestin partially offsets this, which is one reason the combination is preferred over letrozole alone for endometriosis.

Progesterone Levels During Letrozole-Assisted IVF

A subtler question that comes up during IVF is whether letrozole affects the body’s own progesterone production during the stimulation phase, before any supplemental progesterone is given. During ovarian stimulation, some women experience a premature rise in progesterone in the late follicular phase (before egg retrieval), which has been linked to lower pregnancy rates in fresh embryo transfers. One hypothesis was that letrozole, by lowering estrogen, might also help keep progesterone from rising prematurely.

A double-blinded placebo-controlled trial tested this directly and found no difference in the proportion of women who had high progesterone levels in the late follicular phase between the letrozole and placebo groups. The researchers concluded that premature progesterone rise during stimulation is not primarily driven by high estrogen levels. They speculated that letrozole’s estrogen-lowering effect may be offset by the higher LH levels that letrozole induces, resulting in no net change in follicular progesterone.¹²

This matters practically because some IVF clinics have used letrozole co-treatment specifically to try to prevent premature progesterone elevation. The evidence suggests that strategy doesn’t work as hoped, which means the decision to add letrozole to an IVF protocol should be based on other considerations.

How Treatment Timelines Typically Work

In a standard fertility cycle, letrozole and progesterone are rarely taken at the same time on the same day. The typical sequence is: letrozole for five days early in the menstrual cycle (usually days 3 through 7 or days 5 through 9), then monitoring for follicle growth, then a trigger shot to induce ovulation, then progesterone starting a couple of days after ovulation or embryo transfer. By the time progesterone supplementation begins, the letrozole course is already finished and the drug has largely been cleared from the body (letrozole has a half-life of about two days).

In endometriosis protocols, the drugs are genuinely taken simultaneously over weeks or months, since the goal is sustained hormonal suppression rather than a single ovulation event. And in the breast cancer context, the question of adding progesterone to ongoing letrozole therapy would mean concurrent daily use for extended periods, which is the scenario where the most caution is warranted.

Understanding this timeline distinction helps clarify why “taking letrozole and progesterone together” means very different things depending on the clinical scenario. A fertility patient whose letrozole course ended a week ago and who is now taking vaginal progesterone is not really combining the two in any pharmacologically meaningful sense. An endometriosis patient taking both daily is. The safety data, the expected benefits, and the monitoring involved differ accordingly.

What Your Doctor Is Weighing

If you’ve been prescribed both drugs, your provider has likely already considered the specific clinical scenario. For fertility patients, the main variable is whether your situation (PCOS, recurrent pregnancy loss, thin uterine lining) makes progesterone supplementation worth adding to a letrozole cycle. For endometriosis patients, the combination has a reasonable evidence base and the progestin component serves double duty by protecting the uterine lining and bones while also contributing to pain reduction. For breast cancer patients, the default is to avoid progesterone unless you’re enrolled in a clinical trial exploring the combination.

One practical point worth flagging: if you’re researching this question because you’re taking letrozole for breast cancer and are experiencing menopausal symptoms like hot flushes, sleep disruption, or vaginal dryness, do not start progesterone on your own. The WinPro trial’s observation of fewer hot flushes with added progesterone is intriguing, but it hasn’t been established as safe for long-term use in this population. Talk to your oncologist about non-hormonal options for managing those symptoms instead.